Using a non-myeloablative, immunosuppressive, fludarabine-based conditioning regimen, we performed allogeneic peripheral blood stem cell transplants totally on an outpatient basis in four patients (two with chronic myelogenous leukemia, one with acute myelogenous leukemia and one with thalassemia major). The median granulocyte recovery time to 0.5 ؋ 10 
Two immunological barriers must be overcome to successfully establish hematopoietic stem cell (HSC) allografts. One is host-versus-graft disease (HVGD/rejection) and the other is the opposite, graft-versus-host disease (GVHD). Traditionally, the therapeutic regimens administered to prevent HVGD are delivered before transplant and aimed at eradicating the host's immune response as completely as possible, whereas therapeutic regimens to prevent GVHD focus on the grafted donor immune cells, are delivered after transplant and ideally, should only affect those donor immune cells that react with alloantigens for which the donor and host are mismatched. 1 Prevention of HVGD by high-dose conditioning therapy has, as a second goal, the destruction of the patient's underlying disease. Novel allotransplant approaches are based on the concept that current intensive and toxic cytoreductive conditioning therapy can be replaced by non-myelotoxic immunosuppression and that HSC allografts create their own marrow space through GVHD reactions that, in addition, are responsible for the control of certain hematological malignancies. Accordingly, immunosuppression is directed against host cells before transplant and against host and donor cells after transplant; the net effect is the establishment of mutual graft-host tolerance that manifests itself as stable mixed donor-host hematopoietic chimerism.
1 Some investigators have undertaken approaches to reduce regimen-related toxicities.
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Since we have been interested in modifying autologous and allogeneic HSC transplants in order to make them more affordable and available to a larger number of patients, [5] [6] [7] we engaged in a prospective study to assess the feasibility of allogeneic peripheral blood stem cell transplantation on an outpatient basis using a non-myeloablative preparative regimen. Table 1 shows some of the patients characteristics; those with hematological malignancies had received prior chemotherapy and had a Karnofsky score of 100% when the procedure was performed. The donor was an HLA-identical sibling in all instances. Institutional review board approval and written consent was obtained from all the patients.
Materials and methods

Patients and donors
HSC mobilization and apheresis
G-CSF (10 mg/kg/day) was delivered to the donor on days Ϫ5 to ϩ2. The apheresis procedures were performed on days 0, ϩ1 and ϩ2 by means of a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA) or a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield, IL, USA), using the Spin-Nebraska protocol. 8 The endpoint of collection was the processing of 5000 ml of blood/m 2 in each of the three apheresis procedures.
5,7 Gran = granulocytes; plt = platelets; d = days; aGVHD = acute graft-versus-host disease; F = female; M = male; Ph = Philadelphia chromosome; CML = chronic myelogenous leukemia; AML = acute myeloblastic leukemia; * = patient never developed Ͻ20 ϫ 10 9 /l platelets. 2 on days ϩ1, ϩ3, ϩ5 and ϩ11. Oral CsA 5 mg/kg/day was begun on day 4 and continued to day 100, with adjustments according to serum CsA; it was then tapered over 30-60 days. Ondansetron (1 mg i.v. every hour during 4 h after i.v. chemotherapy), ciprofloxacin (250 mg twice a day) and itraconazole (100 mg twice a day) were used in all patients; antibiotics and antimycotics were used until more than 500 granulocytes/l were present. When either patient or donor had anti-cytomegalovirus antibodies, patients were given oral ganciclovir (250 mg three times a day) for 100 days. The products of the PBSC apheresis were reinfused in the outpatient setting on days 0, 1 and 2.
Conditioning and grafting
Apheresis product studies
Enumeration of the total white blood, mononuclear (MNC) and CD34-positive cells was done by flow cytometry 9 in an EPICS Elite ESP apparatus (Coulter Electronics, Hialeah, FL, USA), using the anti-CD34 monoclonal antibody HPCA-2 10 (Becton Dickinson, San José, CA, USA). 10 No purging procedures were performed.
Chimerism studies
In cases 2 and 3 a sex mismatch was present; accordingly, a fluorescent in situ hybridization technique to demonstrate the X and Y chromosomes 11 was performed on days 50 and 60 after the infusion of the apheresis products: 100% of the white cells were from the donor. In cases 1 and 2 ABO system mismatches were present; in order to assess chimerism, a flow cytometry-based approach was used: on day 60, 30 and 49%, respectively, of the red blood cells were from the donor. In case 4, the HLA antigen Cw2, present in the donor and absent in the recipient, was found in 80% of the white cells on day 60. 9 /l platelets, respectively. No patient required red blood cell transfusions and one (patient 3) was given a single prophylactic platelet transfusion. No patient developed febrile neutropenia, veno-occlusive disease, mucositis, severe nausea or diarrhea which would have resulted in hospital admission. All patients are alive at a median of 285 days and have definite evidence of chimerism. Patient number 2 developed biopsy-proven GVHD on day 50, with a limited cutaneous rash that responded to 25 mg/day prednisone. The patient with homozygous beta thalassemia was transplanted from a sibling heterozygous for thalassemia, and has recovered red blood cell counts, remaining transfusion-independent for more than 11 months; she has laboratory data consistent with a heterozygous state for thalassemia. The two patients with CML remain in sustained hematological remission, without detectable Ph chromosomes or BCR/ABL fusion transcripts. Patient number 4 had an hyperleukocytic (468 ϫ 10 9 /l) M2-AML and had achieved a complete remission after three courses of chemotherapy (two courses of daunorubicin/cytarabine and one course of high-dose cytarabine).
Discussion
HSC transplantation has evolved significantly in the past years;
12-14 simplification of the procedures has resulted in the possibility of performing autologous HSC transplantations on an outpatients basis. 7, 14, 15 We have been able successfully to perform HSC allogeneic allografts on an outpatient basis using a non-myeloablative conditioning regimen based on two therapeutic regimens with previously proven efficacy. 2, 3 The major goal of studies that have been reported on allogeneic HSC transplantations using non-myeloablative conditioning regimens is to induce a graft-versus-leukemia (GVL) effect and, as a result, GVHD has been seen in a number of patients. [1] [2] [3] [4] The median approximate cost of the full outpatient procedure in the four cases was 18 000 USD, a figure lower than that for allogeneic transplants using the conventional myeloablative conditioning regimens both in our previous experience in México: 20 000 USD 6 and that of others in the United States: 300 000 USD. 13 We have been interested in changes in the therapeutic approaches to hematological malignancies that may result in both simplification and reduction of costs of the procedures: accordingly, we have shown that the chemotherapy-induced hypoplasia required in the treatment of patients with acute myelogenous leukemia can be safely supported on an outpatient basis, 16 that all-trans retinoic acid in patients with promyelocytic leukemia can be safely delivered on an outpatient basis 17 and that autologous stem cell transplantation can also be performed successfully on an outpatient basis. 7 We have now shown that allogeneic stem cell transplantation can be performed safely on an outpatient basis. It must be stressed that the outpatient transplant program cannot be offered to all patients requiring a stem cell transplantation; only those asymptomatic, fully active, able to stay in their homes, with relatives or friends or in nearby hotels, and with a fair educational level can be offered this program: we have used this non-myeloablative regimen in seven patients, and four of them could be transplanted fully as outpatients. Fundamental to the success of the outpatient approach is the availability of a 7 day-a-week clinic where medications and transfusions can be rapidly and efficiently provided for cytopenias, if required. Finally, it has to be mentioned that the long term-effects of the immunosuppression of the conditioning schedule are currently unknown.
Note added in proof
Twelve more patients have been allografted using this method; the procedures were completed on an outpatient basis in eight and the 13-month survival is 68%.
